Using biomarkers in the assessment of airways disease

被引：36
作者：
Taylor, D. Robin [1 ]
机构：
[1] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2011年 / 128卷 / 05期
关键词：
Airways disease; asthma; biomarkers; chronic obstructive pulmonary disease; exhaled nitric oxide; induced sputum; performance characteristics; validation; EXHALED NITRIC-OXIDE; RANDOMIZED CONTROLLED-TRIAL; OBSTRUCTIVE PULMONARY-DISEASE; NECROSIS-FACTOR-ALPHA; SURROGATE END-POINTS; C-REACTIVE PROTEIN; CHILDHOOD ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; PERSISTENT ASTHMA; EOSINOPHILIC ASTHMA;
D O I：
10.1016/j.jaci.2011.03.051
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
A biomarker provides a window on underlying disease activity. This is helpful when the pathology, treatment response, or both are heterogeneous or when trying to interpret nonspecific respiratory symptoms in patients with comorbidities. The successful application of a biomarker result is critically dependent on the specific question being addressed and the performance characteristics of the biomarker in relation to that question in the context of pretest probabilities. Negative prediction might be the best way to use a biomarker, such as a D-dimer, pro-brain natriuretic peptide, and exhaled nitric oxide. In this review the role of biomarkers in airways disease ( notably induced sputum eosinophils and exhaled nitric oxide) is considered in relation to risk stratification, identification of treatment responders, identification of a clinical phenotype, monitoring of disease, and new drug development. (J Allergy Clin Immunol 2011;128:927-34.)
引用
收藏
页码：927 / 934
页数：8
相关论文
共 77 条
[1]  
[Anonymous], EUR RESP J
[2]  
[Anonymous], 2007, J ALLERGY CLIN IMMUN
[3]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[4]   Can guideline-defined asthma control be achieved? The gaining optimal asthma control study [J].
Bateman, ED ;
Boushey, HA ;
Bousquet, J ;
Busse, WW ;
Clark, TJH ;
Pauwels, RA ;
Pedersen, SE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (08) :836-844
[5]   Evidence of a role of tumor necrosis factor α in refractory asthma [J].
Berry, MA ;
Hargadon, B ;
Shelley, M ;
Parker, D ;
Shaw, DE ;
Green, RH ;
Bradding, P ;
Brightling, CE ;
Wardlaw, AJ ;
Pavord, ID .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (07) :697-708
[6]   Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma [J].
Berry, Mike ;
Morgan, Angela ;
Shaw, Dominick E. ;
Parker, Deborah ;
Green, Ruth ;
Brightling, Christopher ;
Bradding, Peter ;
Wardlaw, Andrew J. ;
Pavord, Ian D. .
THORAX, 2007, 62 (12) :1043-1049
[7]   Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma [J].
Bossley, C. J. ;
Saglani, S. ;
Kavanagh, C. ;
Payne, D. N. R. ;
Wilson, N. ;
Tsartsali, L. ;
Rosenthal, M. ;
Balfour-Lynn, I. M. ;
Nicholson, A. G. ;
Bush, A. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (05) :1052-1059
[8]   Subclinical phenotypes of asthma [J].
Bradding, Peter ;
Green, Ruth H. .
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 10 (01) :54-59
[9]   Targeting TNF-α:: A novel therapeutic approach for asthma [J].
Brightling, Christopher ;
Berry, Mike ;
Amrani, Yassine .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (01) :5-10
[10]   A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma [J].
Busse, William W. ;
Ring, Johannes ;
Huss-Marp, Johannes ;
Kahn, Jean-Emmanuel .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (04) :803-813
12345678